For #Media and #Investors Don’t miss out on MoonLake’s Capital Market Update this Wednesday, September 11, 2024 from 9:00 – 10:30 EST/06:00 – 07:30 PST/15:00 – 16:30 CET. Connect with our leadership as we break down the latest on our Phase 3 programs in #HidradenitisSuppurativa and #PsoriaticArthritis. We’ll also dive into pipeline updates, our financials, and our views on fresh market opportunities. Ready to learn more? Visit https://lnkd.in/dWNtpQgj Or please register for the webcast online here: https://lnkd.in/dikdfHNk Share our commitment to improving outcomes for patients? Reach out to [email protected] and let’s explore how we can achieve more together. #MLTX #MoonLake #HS #PsA #IL17-A #IL17-F
MoonLake Immunotherapeutics (NASDAQ: MLTX)
Biotechnologieforschung
Zug, Zug 4.393 Follower:innen
Creating next-level therapies for inflammatory skin and joint diseases with Nanobody® science
Info
MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
- Website
-
http://www.moonlaketx.com
Externer Link zu MoonLake Immunotherapeutics (NASDAQ: MLTX)
- Branche
- Biotechnologieforschung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Zug, Zug
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2021
- Spezialgebiete
- Immunotherapy, inflammatory skin & joint diseases, partnering, IL17A / F, #MLTX, #Nanobody, #HS, #PsA und #IL17
Orte
-
Primär
Dorfstrasse
29
Zug, Zug 6300, CH
Beschäftigte von MoonLake Immunotherapeutics (NASDAQ: MLTX)
Updates
-
🚀 Exciting News from MoonLake! MoonLake is growing fast and we’re looking for passionate, talented individuals to join our team! If you’re ready to work in a unique biotech environment where innovation meets opportunity, this is your chance. Explore great opportunities with us that offer, cutting-edge biotech projects, supportive, dynamic work culture and hybrid working across all three of our Cambridge UK, Porto PT and Zug CH offices. Ready to take the leap? Apply now and be part of something extraordinary! https://lnkd.in/ebgF4BDW 🚀 #MoonLake #NowHiring #BiotechCareers #GoBeyond #CareerOpportunities #Innovation #JobAlert 🚀Senior Manager Clinical Operations 🚀Senior Manager Device Quality 🚀Senior Technical Manager Drug Product 🚀Director PV & Safety 🚀Senior Manager CMC Regulatory Affairs 🚀Manager Biostatistics 🚀Clinical Trial Administrator 🚀Senior Specialist Corporate Communications 🚀Senior Manager Bioanalysis Clinical Development
-
For #media #investors: We are honored to announce that Professor Georg Schett, University of Erlangen-Nürnberg, Germany will present data from MoonLake's Phase 2 ARGO trial at the 14th International Congress on Spondyloarthritides, which is taking place this week in Ghent, Belgium. The abstract, which is scheduled to be presented at 12.34pm on Saturday September 7, was one of only a small number selected for oral presentation. The presentation will focus on Psoriatic Arthritis (PsA) disease activity outcomes at Week 12 of the trial. Naomi Attar, Matthew Thomas PhD and Sónia Guerra Gomes from our Medical Affairs team will be onsite for the duration of the meeting and look forward to connecting with global experts on Psoriatic Arthritis and Axial Spondyloarthritis. For more details on the congress, visit: https://lnkd.in/dKGc5s-N #Spondyloarthritis #MLTX #MoonLake #Immunotherapeutics #InflammatoryDiseases
-
For #media #investors: MoonLake is proud to announce that two abstracts have been accepted for presentation at this week's 53rd Annual ESDR (European Society of Dermatological Research) Meeting in Lisbon, Portugal: - A significant pro-inflammatory role for IL-17F in dermal tunnels: Implications for therapeutic interventions in hidradenitis suppurativa (HS)' (Poster 350) - In-depth characterization of enhanced IL-17 signaling in hidradenitis suppurativa: Comparison of perilesional skin with inflammatory nodules and tunnels' (Poster 291) We’ll also be presenting highlights from the ‘In-depth characterization of enhanced IL-17 signaling in hidradenitis suppurativa: Comparison of perilesional skin with inflammatory nodules and tunnels’ poster during Poster Walk Session 3 on Thursday September 5 (4.30–5.30 pm, Room 1.05). Eva Cullen PhD and Sara Souto Pereira from our Medical Affairs team will be onsite for the duration of the meeting and look forward to sharing our latest research with global experts on translational dermatology. If you’re attending the event and would like to connect, reach out to us at [email protected]. For more details on the ESDR meeting, visit: https://esdrmeeting.org/ #ESDR #MLTX #MoonLake #Immunotherapeutics #skindisease #dermatology
-
For #media #investors: Today, we issued our second quarter 2024 results and announced that we will host a Capital Markets Update virtually on September 11. We continue to make significant progress in our clinical programs. This quarter, we initiated the Phase 3 VELA program of our Nanobody® in hidradenitis suppurativa (HS) and outlined the clinical plan for our Phase 3 program in psoriatic arthritis (PsA) following positive regulatory feedback from both the FDA and EMA. We ended the quarter with $519.8 million in cash, cash equivalents, and short-term marketable debt securities, providing a robust financial position to support a roadmap rich in potential catalysts. We look forward to providing further insights into our market opportunities and trial execution at our Capital Markets Update. Read the full announcement here: https://lnkd.in/dsf5jCvj #MLTX #MoonLake #psoriasis #nanobody #HS #PsA #IL17A #IL17F #inflammatorydiseases
-
For #media #investors: We are proud to be a corporate partner of Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - GRAPPA, whose Annual Meeting and Trainee Symposium will take place in Seattle, US this week. Eva Cullen PhD and Naomi Attar, from our Medical Affairs team, will be attending the meeting and look forward to strengthening our partnership with GRAPPA as we strive toward our shared aims of enhancing research, diagnosis and treatment of psoriatic arthritis. We hope to see you there! If you are interested in arranging a meeting, please contact us at [email protected]. #MoonLake #MLTX #PsA #Congress #Conference #HS #IL-17 #Seattle #GRAPPA2024
-
For #media #investors: Our Medical Affairs team members Eva Cullen PhD, Naomi Attar and Sónia Guerra Gomes are attending IFPA’s 7th World Psoriasis & Psoriatic Arthritis Conference this week in Stockholm. MoonLake clinical trial data is set to be a highlight of the conference — with our abstract one of only six submissions selected by the IFPA scientific committee for an oral presentation. The presentation will report Week 12 multidomain outcomes in the PsA ARGO trial, with Prof. Joseph F Merola MD MMSc (Chair, Dermatology and Professor, Dermatology, Medicine & Rheumatology; UT Southwestern Medical Center, Dallas, TX, USA) as the presenting author. Morning plenary session, June 28, 2024 Main Auditorium, Stockholm Waterfront Congress Center We hope to see you there! If you are interested in arranging a meeting, please contact us at [email protected]. #MoonLake #MLTX #PsA
-
For #media #investors: We were thrilled to win Best Communication Award at the European Mediscience Awards 2024! This achievement would not have been possible without the support, encouragement, and inspiration from the incredible network of the MoonLake Communications Team! It’s also a testament to the power of teamwork and effective communication! Please find below our CFO, Matthias Bodenstedt with Patrícia Marques de Sousa, our Director of Corporate Affairs accompanied by Mary-Jane Elliott, Managing Partner, ICR Consilium, Nina Hossain and Michael White, Head of Life Sciences and Healthcare, HSBC Innovation Banking. Congratulations to all the other award winners and nominees! #MLTX #MoonLake #nanobody #HS #PsA #IL17A #IL17F
-
For #media #investors: Our CFO Matthias Bodenstedt is attending the Stifel Europe Healthcare Summit taking place in Lyon on 25-27 June. Contact us at [email protected] if you are interested in meeting. #MoonLake #MLTX #IL17A #IL17F #HS #PsA #nanobody
-
For #media #investors: Thank you EULAR - European Alliance of Associations for Rheumatology Congress for another engaging meeting! We thoroughly enjoyed hearing about the latest advances in #rheumatology and discussing these with some of the brightest minds in the field. Here are some photos of our team in action and Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, presenting key Week 12 efficacy and safety outcomes from the ARGO trial. #MoonLake #MLTX #PsA #HS #IL17F #IL17A
Ähnliche Seiten
Finanzierung
Letzte Runde
Kapitalerhöhung nach Börsengang400.000.000,00 $